Belvedere Trading
KALV

Belvedere Trading’s KalVista Pharmaceuticals KALV Stock Holding History

Belvedere Trading’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-18,200
Closed -$223K – 823
2023
Q4 		$223K Buy
18,200
+15,800
+658% +$144K ﹤0.01% 318
2023
Q3 		$23.1K Buy
+2,400
New +$24.5K ﹤0.01% 503

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Belvedere Trading's KALV Position: Q1 2024 in Review

Belvedere Trading sold out of KalVista Pharmaceuticals (KALV) in Q1 2024, closing a stake of 4,170 shares — an estimated $51.1K sold.

Belvedere Trading first reported a position in KALV in Q3 2023 and held it in 2 quarters. The position peaked at $106K in Q3 2023. 128 funds tracked by Wall St. Rank hold KALV as of Q1 2024.

  • Belvedere Trading reported no remaining KalVista Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Belvedere Trading sold 4,170 KalVista Pharmaceuticals shares in Q1 2024, an estimated $51.1K.
  • Belvedere Trading first reported a position in KalVista Pharmaceuticals in Q3 2023 and held it in 2 quarters.
  • Belvedere Trading's KalVista Pharmaceuticals position peaked at $106K in Q3 2023.
  • 128 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2024.

Based on Belvedere Trading's 13F filing for Q1 2024, filed 9 May 2024.